Chemed Corp (CHE)

Investment Committee Summary

Investment Thesis

Chemed provides hospice services to patients through a network of physicians, nurses, home health aides, social workers, clergy and volunteers across the United States. The economics are simple to state and hard to control: revenue is essentially a reimbursement rate multiplied by patient days, and cost is clinical labour. The company therefore sets neither its price nor, ultimately, its largest input cost. At $500 on 10 October 2026 the shares are fairly valued against the engine's triangulated fair value (-9%), the engine reaches HOLD, and the stock trades close to its 52-week high. The market pays 20 times forward earnings for an operating margin near 13% (reported GAAP, TTM to Jun 2026), and the balance sheet is close to unlevered with only net debt of ~$0.2B — genuinely unusual in health services and a real part of the quality case. The variable that decides the outcome is the gap between reimbursement updates and clinical wage inflation. The most damaging risk is that this gap is set by two independent parties, so an adverse move in either one compresses the margin without any operational failure by the company.

Narrative drafted 2026-08-16 by claude-opus-5 under supervision; reviewed by Marinus 2026-08-16.

The dashboard below is the whole argument on one page: spot ($500) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The mechanism is a squeeze from both ends of a margin the company does not control. Reimbursement rates are set administratively and adjust on a policy timetable; clinical wages are set by a national labour market for nurses and aides that has been structurally tight. When wage growth exceeds the rate update — which requires no recession and no competitive event — an operating margin near 13% (reported GAAP, TTM to Jun 2026) compresses directly, and there is no pricing lever available to offset it. Volume offers limited defence, because serving more patients requires proportionally more clinicians. Regulatory intervention is the structural version: a change in eligibility rules, audit intensity or payment methodology can reset the revenue base permanently. Valuation converts these into an outsized equity move — 20 times forward earnings near the top of the 52-week range prices durable margins, and a modest, plausible squeeze de-rates both the earnings and the multiple. The model's structural branch targets a level below the 52-week low.

Key Debate

Gross Margin explains 48% of Monte Carlo outcome variance — the single variable that decides which side is right.

What the Market Is Pricing In

At the current price, the market pays 19.6× consensus forward EPS, vs the house DCF terminal 17.0×, and a peer median 38.8×. The house DCF sits 17% below spot, so the market is pricing in more than the house case — roughly 2.2pp of revenue CAGR.

Variant perception: the house view is below-consensus, and the thesis is primarily multiple-driven.

Scenario Analysis

The scenario tree spans a structural 'Structural — Reimbursement / In-House Testing' downside ($224) to a 'Bull — Re-Rate' bull case ($902); the probability-weighted blend (PWEV $502) is +1% versus spot.

SBC charge: scenario targets are gross per-share prices; the PWEV is reduced by one year of stock-based-compensation dilution (1.5% of shares, on SBC ≈ 2% of revenue), trimming the gross PWEV of $510 to $502 (-1.5%). SBC is charged once, as dilution — never also deducted from FCF.

Scenario rationale — the driver path behind every target:

• Structural — Reimbursement / In-House Testing (20%, $224). Structural impairment — reimbursement / insourcing: earnings AND the multiple compress together. Target sits below the 52-week low by construction.
• Volume Recession (17%, $381). Cyclical downturn — outsourced service volume + reimbursement per unit + mix + tuck-in M&A weakens for 1–2 years before normalising.
• Base — Volume + Acquisitions (35%, $529). Mid-cycle — normalised outsourced service volume + reimbursement per unit + mix + tuck-in M&A; disciplined capital allocation; steady returns.
• Growth — Advanced-Diagnostics / M&A (20%, $714). Upside — mix upgrade + M&A lifts earnings above mid-cycle; the multiple expands modestly.
• Bull — Re-Rate (8%, $902). Upside tail — sustained tight conditions or a structural re-rate on mix upgrade + M&A.

Valuation Triangulation

Three weighted anchors — an intrinsic dcf, a scenario-weighted pwev and a monte carlo median (student-t + regime switching) — read them with their basis in mind. The Monte Carlo, the scenario PWEV, any DCF's exit-multiple terminal and any peer re-rate key off a market multiple, so they are not independent; only a DCF's explicit-period cash flows are multiple-free, and its terminal usually carries most of its value. The discipline is to read the spread, not to treat three numbers as three independent votes.

The house blend DECLARES five anchor weights — DCF 35%, scenario PWEV 25%, Monte Carlo 15%, sum-of-parts 15%, peer re-rate 10%. For this name sum-of-parts is not computed, so 15% of the declared weight is redistributed across the anchors that exist — which is why the weights above differ from the declared ones. The fair value is unaffected by this disclosure; the blend has always worked this way. The company-lever row in the Sensitivity section is an illustrative EBIT × multiple value, not a sum-of-parts anchor.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

peer P/E re-rate excluded from the weighted blend — diverges >55% from the Monte-Carlo / scenario core. For a high-leverage equity the per-share DCF (enterprise value less large net debt) is hypersensitive to the terminal multiple; a peer re-rate across heterogeneous margins is apples-to-oranges. Shown above for reference; the blend leans on the multiple-discipline and scenario anchors.

Monte Carlo — the outcome distribution

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $456 and 42% of paths finish above spot. The variance decomposition shows the gross margin is the dominant swing factor (48% of variance). The fundamental driver, not the multiple, sets the spread — a cleaner setup.

DCF — explicit-period cash flows with an exit-multiple terminal

A 5-year cash-flow path discounted at a WACC of 8.5%, plus a terminal value of final-year FCF × 17.0x — a terminal multiple equal to 0.85 × the base multiple that the Monte Carlo and the scenario tree also use → $416. The terminal value is 75% of enterprise value, so this anchor moves with the multiple assumption. The heaviest anchor in this blend (47%); because its terminal is a market multiple, it is not independent of the multiple-driven anchors.

Peer benchmarking — relative value

Against its 3 peers in the same GICS sub-industry, re-rating to their median forward multiple (P/E 38.8x) implies $988. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Excluded from the weighted blend — shown only as a market cross-check.

Across all anchors the spread is 114% of the median — wide (genuine disagreement — the blend carries low valuation confidence).

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × model op-margin Δ (Δ applied to the DCF's house margin path)

Tornado — DCF/share swing by driver (widest first)

Company lever — value at the base multiple vs Diagnostics & Outsourced Health Services multiple (base 21.0x)

Illustrative: segment EBIT × multiple, plus net cash, over basic shares — it does not enter the triangulated fair value.

Peer Quality & Weighting

Quality-weighted forward P/E: 28.2× (simple median 38.8×). Direct peers count 100%, segment 50%, broad 25%.

Valuation-anchor screen: Peer (fwd P/E) (valid but extreme (>100% over median)). Anchor median 456.4. Extreme/excluded anchors carry no headline weight.

Historical-range cross-check: 52-week range $365–$557, centre $451 (-10% vs spot); spot sits at the 70th percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

That ratio is (triangulated FV ÷ price − 1) ÷ (1 − 'Structural — Reimbursement / In-House Testing' target ÷ price). 'Structural — Reimbursement / In-House Testing' ($224, probability 20%) is the lowest-target scenario in the tree, taken gross of SBC dilution. With a leg missing the ratio is withheld rather than computed from a magnitude. Bull case (Bull — Re-Rate): $902.

Company Overview & Business Model

Chemed Corp — HEALTHCARE · MEDICAL CARE FACILITIES. Chemed Corporation provides hospice and hospice services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers across the United States. The company is headquartered in Cincinnati, Ohio.

Company description as supplied by Alpha Vantage; not checked against the company's filings.

How it makes money.

† Model margin = gross margin − the opex ratio calibrated so the Monte Carlo median EPS meets the EPS target; it is not a reported operating margin.

Reported operating margin (GAAP): 13.4% for the fiscal year ended 2025-12-31; 13.5% TTM to 2026-06-30 (Alpha Vantage INCOME_STATEMENT).

Edge. Narrow moat — inferred from a 13% (reported GAAP, TTM to Jun 2026) operating margin and the diagnostics & outsourced health services business model. Some pricing power / share stability; terminal multiple near the market.

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

For comparison, the company's reported GAAP operating margin was 13.4% for the fiscal year ended 2025-12-31; 13.5% TTM to 2026-06-30 (Alpha Vantage INCOME_STATEMENT).

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Industry Context — Health Care — Services

This name sits in the Health Care — Services cluster as a diagnostics & outsourced health services name. outsourced service volume + reimbursement per unit + mix + tuck-in M&A. Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.

Value chain: BTSG (diagnostics & outsourced health services) · HIMS (diagnostics & outsourced health services) · CHE (diagnostics & outsourced health services) · SHC (diagnostics & outsourced health services)

Mapping note: name-level 'Structural — Reimbursement / In-House Testing' (20%) + 'Volume Recession' (17%) map to cluster Reimbursement / Disintermediation Pressure (37%); name-level 'Growth — Advanced-Diagnostics / M&A' (20%) + 'Bull — Re-Rate' (8%) map to cluster Upside — Specialty / M&A Re-Rate (28%) — the cluster row is the SUM of the mapped scenario probabilities, not a different estimate.

On the cluster's key downside — Reimbursement / Disintermediation Pressure — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.

Structure: Shared State — The Health Care — Services cycle is the shared macro driver. Driver — drug/lab volumes + reimbursement + thin-margin distribution & specialty mix. Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).

Balance Sheet & Liquidity

Balance-sheet data as of 2025-12-31 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 2% of revenue; cash conversion (OCF/NI) 146% — cash-backed.

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q1): management +0.16 vs analyst floor +0.00 → delta +0.16 (n=30 mgmt / 14 Q&A; 5th pctile across the S&P book, z -1.6).

Flag: CANDID — management unusually candid/cautious vs peers (relatively low spin).

News (last 365d, 283 articles): avg ticker sentiment +0.08 (bullish 16% / bearish 9%)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Catalyst Calendar

• 2026-10-27 (~18d) — Quarterly earnings — est. EPS $5.93 (AV EARNINGS_CALENDAR)

Forecast Track Record

• EPS surprise: beat 50% of the last 8 quarters; average surprise -1.4%.

Catalyst Timeline

5 catalysts in the next 90 days (of 12 tracked). Importance 1–3; confidence 0–1.

_Sources: extended.catalysts, data/catalysts/.json, data/catalysts/macro.json, AV DIVIDENDS, opex 3rd-Friday calc.

Scenario Macro & Key Risks

Decision Rules (Machine-Checked)

Stance: Hold — 0 bullish / 0 bearish / 1 caution rules triggered of 6 evaluable (0 lacked data).

Machine-checked rules over disclosed inputs. The authored falsification triggers elsewhere in this report are analyst judgment and are NOT evaluated here. The stance is what the model's own rules read on this name; it does not modify the published research rating, and it is not personal financial advice.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• Organic revenue growth / order backlog < flat-to-negative for two consecutive quarters (2 consecutive prints). Sustained demand rollover breaks the base case toward the recession scenario.
• FY revenue ($B) < 2.55 (next reported fiscal year). (rationale withheld pending re-authoring — frozen figure or verdict)
• Probability-weighted fair value (PWEV) at the next re-run < 499.82 (any scheduled re-run). (rationale withheld pending re-authoring — frozen figure or verdict)

Fact / Inference / Speculation

• FACT: Spot $500; 52-week range $365–$557; engine rating HOLD; house target $502 (+1%). (source: Alpha Vantage 2026-10-09, 10 October 2026)
• INFERENCE: Triangulated FV $453 (-9% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the DCF anchor sits below the multiple-discipline core.
• SPECULATION: At current prices the embedded bet is that Gross Margin keeps surprising favourably — an operating call the next two prints will test.

Conviction Score

Research Conviction measures the strength and quality of the research setup — input coverage, financial quality, valuation support, process agreement. It is NOT the probability that the recommendation succeeds; the forecast track record section is the evidence on that.

61.8/100 (confidence band 52.8–70.8), 67th percentile of 893 covered names (as of 2026-10-09). Weighted composite under config ros-1.20.0 — every component and its inputs below.

Score history: 61.3 → 61.4 → 61.6 → 61.6 → 61.5 → 61.7 → 61.8 → 61.9.

Probability-Weighted Return Profile

Horizon: 1 year — at this horizon CAGR equals total return by definition. Expected values are the probability-weighted sums over the full scenario set below.

The gross expected return is the probability-weighted scenario return (it reconciles to the gross PWEV); the diluted figure applies the SBC share-count charge and matches the published PWEV-based target.

Expected Alpha

Expected return minus the return this name is REQUIRED to deliver for its risk (1-year horizon). Constants are pre-registered (preregistered-static (amendment #2, 2026-07-29); not fitted to MCH outcomes).

A negative expected alpha does not change the rating — it says the expected return does not clear the risk-adjusted hurdle at today's price. Rating mechanics are unchanged by this section.

Probability Cross-Checks

Not authoritative. The scenario probabilities in this report are AUTHORED — a judgement about how the world might go, not a measurement. Nothing below modifies them, the target, the rating or any position size. These checks ask only whether anything outside our own model agrees with us; where it does not, that is information for the reader, not a correction we have quietly applied.

Authored set: 5 scenarios, probabilities summing to 1.0, mean target $509.88.

Flagged for review: internal coherence (authored mass vs Monte Carlo). A flag marks a disagreement worth understanding — it does not imply either side is wrong.

Factor Exposures

Cross-sectional percentiles over 893 covered names (style scores sector-demeaned; thematic = return-beta to the theme's proxy ETF). 50 = estate median.

Market interaction: correlation vs SPY +0.13, vs QQQ +0.05 (trailing ~1y daily returns).

Rating Bridge

Rating = HOLD because:

• Probability-weighted scenario value implies +1% vs spot
• Monte Carlo median implies -9% vs spot
• DCF fair value (exit-multiple terminal) implies -17% vs spot
• Bear case (Structural — Reimbursement / In-House Testing) downside is -55% vs spot
• Net: the valuation anchor itself sits 9.4% below spot, so there is no reward leg to weigh against the bear case and the reward-to-risk ratio is withheld rather than computed off a negative upside. The rating is not asymmetric enough for a Buy and not impaired enough for a Sell — hence Hold.

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 5% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 8.5% · Σ PV(FCF) $1B + PV(terminal) $4B = EV $6B; − net debt $0.2B → equity $5B ÷ diluted shares $0.01B = $416/share (exit-multiple terminal).

• Gordon terminal → $417/share — a single-point perpetual-growth cross-check at g = 2.5% (one growth rate, not a range; it is not in the blend).
• Incremental ROIC on the forecast capex ≈ 8% vs WACC 8.5% → below WACC — the incremental build is value-dilutive.

Peer set

Implied prices at the peer medians: same-sub-industry median fwd P/E → $988; EV/Rev → $631.

Weighted fair-value math

Assumption Register

Sensitivity-ranked drivers (widest fair-value swing first): Model op margin ±3pp (153.0); Terminal × ±15% (98.0); Revenue CAGR ±3pp (95.0); Capex intensity ±15% (50.0); WACC ±1pp (36.0).

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Research Provenance

Load-Bearing Assumptions

DCF: WACC 8.5%, terminal multiple 17×, FY+5 revenue $3B. Triangulation leans 47% on DCF, 33% on PWEV, 20% on the Monte Carlo median.